Virtual Event | March 28, 2023

Revolutionary Incrementalism: Future-Proofing mRNA Drug Manufacturing

Source: Cytiva

Arguably, one of the greatest challenges facing mRNA therapeutics companies is establishing a well-defined and high-quality drug product manufacturing process—especially when there are few marketed products and limited-to-no dedicated regulatory guidance.

In this panel discussion, John Stubenrauch, Ph.D., Chief Operations Officer at Nutcracker Therapeutics, Hari Pujar, Ph.D., Chief Operating Officer at Tessera, and Anna Rose Welch, Chief Editor at Cell & Gene Collaborative discuss go-to best practices, suggestions, and experiences for prioritizing and streamlining technical operations endeavors to prepare for the clinic and, eventually, the commercial market.

access the Virtual Event!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Advancing RNA? Subscribe today.

Subscribe to Advancing RNA X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Advancing RNA